

Verteporfin

Catalog No: tcsc1950



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

129497-78-5

Formula:

$C_{41}H_{42}N_4O_8$

Pathway:

Stem Cell/Wnt;Autophagy

Target:

YAP;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : 8 mg/mL (11.13 mM; Need ultrasonic); H2O :

Alternative Names:

CL 318952

Observed Molecular Weight:


718.79

Product Description

Verteporfin is a benzoporphyrin derivative monoacid ring A, and can inhibit the activity of **YAP**.

In Vitro: Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI_{50}) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI_{50} for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 μ M, 2.11 μ M, and 5.61 μ M, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells^[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and paclitaxel (PTX) shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T^[2].

In Vivo: Verteporfin (10 mg/kg, c.s.c.) and dasatinib significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!